A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.

Also called NCT03361501

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 278 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03361501
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03361501. Randomized; double masking; primary purpose treatment. Start 2018-02-01 (actual); primary completion 2019-09-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
Acronym
TRILOGY 2
Condition
Hypertriglyceridemia
Intervention (Drug)
CaPre
Intervention (Drug)
Placebo
Lead sponsor
Grace Therapeutics Inc. (class: industry)

Record details

Record id
cardio:ct-nct03361501
Content hash
34b4200e24232b45007f4147d2613d13b9c1b43dccf4a40a816adb1820ba4473